Raymond Sawaya

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11968053/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Circumferential sulcus-guided resection technique for improved outcomes of low-grade gliomas. Journal of Neurosurgery, 2022, , 1-11.	1.6	3
2	Imaging characteristics of 4th ventricle subependymoma. Neuroradiology, 2022, , 1.	2.2	1
3	A first-in-human Phase I trial of the oral p-STAT3 inhibitor WP1066 in patients with recurrent malignant glioma. CNS Oncology, 2022, 11, CNS87.	3.0	15
4	Challenges in glioblastoma immunotherapy: mechanisms of resistance and therapeutic approaches to overcome them. British Journal of Cancer, 2022, 127, 976-987.	6.4	26
5	A Crowdsourced Consensus on Supratotal Resection Versus Gross Total Resection for Anatomically Distinct Primary Glioblastoma. Neurosurgery, 2021, 89, 712-719.	1.1	19
6	Pediatric neurosurgery at Texas Children's Hospital: the legacy of Dr. William R. Cheek. Journal of Neurosurgery: Pediatrics, 2021, , 1-7.	1.3	0
7	Thalamic gliomas in adults: a systematic review of clinical characteristics, treatment strategies, and survival outcomes. Journal of Neuro-Oncology, 2021, 155, 215-224.	2.9	17
8	Neurosurgical management of patients with brain metastasis. Neurosurgical Review, 2020, 43, 483-495.	2.4	45
9	Perilesional Resection of Clioblastoma Is Independently Associated With Improved Outcomes. Neurosurgery, 2020, 86, 112-121.	1.1	35
10	Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages. Neuro-Oncology, 2020, 22, 539-549.	1.2	98
11	Glioblastoma-mediated Immune Dysfunction Limits CMV-specific T Cells and Therapeutic Responses: Results from a Phase I/II Trial. Clinical Cancer Research, 2020, 26, 3565-3577.	7.0	30
12	Surgical Resection for Brain Metastases. , 2020, , 191-198.		0
13	Antitumor immune response during glioma virotherapy. Neuro-Oncology, 2019, 21, 1087-1088.	1.2	О
14	En Bloc Versus Piecemeal Resection of Metastatic Brain Tumors. , 2019, , 303-311.		2
15	Multi-center study finds postoperative residual non-enhancing component of glioblastoma as a new determinant of patient outcome. Journal of Neuro-Oncology, 2018, 139, 125-133.	2.9	26
16	Glioblastoma stem cell-derived exosomes induce M2 macrophages and PD-L1 expression on human monocytes. Oncolmmunology, 2018, 7, e1412909.	4.6	247
17	Mesenchymal stem cells as natural biofactories for exosomes carrying miR-124a in the treatment of gliomas. Neuro-Oncology, 2018, 20, 380-390.	1.2	173
18	Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma. Journal of Clinical Oncology, 2018, 36, 1419-1427.	1.6	477

#	Article	IF	CITATIONS
19	A Time-Tested Information System in Neurosurgical Oncology. Frontiers in Oncology, 2018, 8, 593.	2.8	3
20	Biological subtypes and survival outcomes in breast cancer patients with brain metastases in the targeted therapy era. Neuro-Oncology Practice, 2018, 5, 161-169.	1.6	6
21	A Coclinical Radiogenomic Validation Study: Conserved Magnetic Resonance Radiomic Appearance of Periostin-Expressing Glioblastoma in Patients and Xenograft Models. Clinical Cancer Research, 2018, 24, 6288-6299.	7.0	74
22	Profiles of brain metastases: Prioritization of therapeutic targets. International Journal of Cancer, 2018, 143, 3019-3026.	5.1	31
23	Neurosurgical Management of Single Brain Metastases. , 2018, , 431-447.		1
24	Neurosurgical management of brain metastases. Clinical and Experimental Metastasis, 2017, 34, 377-389.	3.3	40
25	Silent Sentence Completion Shows Superiority Localizing Wernicke's Area and Activation Patterns of Distinct Language Paradigms Correlate with Genomics: Prospective Study. Scientific Reports, 2017, 7, 12054.	3.3	9
26	Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial. Lancet Oncology, The, 2017, 18, 1040-1048.	10.7	537
27	Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype. JCI Insight, 2016, 1, .	5.0	356
28	Radiomic Texture Analysis Mapping Predicts Areas of True Functional MRI Activity. Scientific Reports, 2016, 6, 25295.	3.3	26
29	Technical principles in glioma surgery and preoperative considerations. Journal of Neuro-Oncology, 2016, 130, 243-252.	2.9	42
30	Association of the Extent of Resection With Survival in Glioblastoma. JAMA Oncology, 2016, 2, 1460.	7.1	710
31	The influence of maximum safe resection of glioblastoma on survival in 1229 patients: Can we do better than gross-total resection?. Journal of Neurosurgery, 2016, 124, 977-988.	1.6	480
32	SURG-04BETTER IN THE BUCKET: EXTENSIVE RESECTION IMPROVES SURVIVAL IN GLIOBLASTOMA- A SYSTEMATIC REVIEW AND META-ANALYSIS OF THE WORLD'S LITERATURE. Neuro-Oncology, 2015, 17, v214.4-v215.	1.2	0
33	Stat3 orchestrates interaction between endothelial and tumor cells and inhibition of Stat3 suppresses brain metastasis of breast cancer cells. Oncotarget, 2015, 6, 10016-10029.	1.8	50
34	Mir-21–Sox2 Axis Delineates Glioblastoma Subtypes with Prognostic Impact. Journal of Neuroscience, 2015, 35, 15097-15112.	3.6	53
35	Breast Cancer With Brain Metastases: Clinicopathologic Features, Survival, and Paired Biomarker Analysis. Oncologist, 2015, 20, 466-473.	3.7	70
36	Impact of surgical methodology on the complication rate and functional outcome of patients with a single brain metastasis. Journal of Neurosurgery, 2015, 122, 1132-1143.	1.6	100

#	Article	IF	CITATIONS
37	Genetic, epigenetic, and molecular landscapes of multifocal and multicentric glioblastoma. Acta Neuropathologica, 2015, 130, 587-597.	7.7	68
38	Metastatic Brain Tumors:Viewpoint—Surgery. , 2015, , 233-240.		1
39	Impact of Preoperative Functional Magnetic Resonance Imaging during Awake Craniotomy Procedures for Intraoperative Guidance and Complication Avoidance. Stereotactic and Functional Neurosurgery, 2014, 92, 315-322.	1.5	39
40	Therapeutic targets in subependymoma. Journal of Neuroimmunology, 2014, 277, 168-175.	2.3	21
41	Awake craniotomy for gliomas in a high-field intraoperative magnetic resonance imaging suite: analysis of 42 cases. Journal of Neurosurgery, 2014, 121, 810-817.	1.6	64
42	Preoperative Imaging to Predict Intraoperative Changes in Tumor-to-Corticospinal Tract Distance. Neurosurgery, 2014, 75, 23-30.	1.1	38
43	IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro-Oncology, 2014, 16, 81-91.	1.2	370
44	Sustained activation of SMAD3/SMAD4 by FOXM1 promotes TGF-β–dependent cancer metastasis. Journal of Clinical Investigation, 2014, 124, 564-579.	8.2	155
45	Diagnostic discrepancies in malignant astrocytoma due to limited small pathological tumor sample can be overcome by IDH1 testing. Journal of Neuro-Oncology, 2014, 118, 405-412.	2.9	28
46	Real-Time Atlas-Based Stereotactic Neuronavigation. Neurosurgery, 2014, 74, 128-134.	1.1	11
47	Factors Responsible for Local Recurrence of Brain Metastasis. Tumors of the Central Nervous System, 2014, , 187-193.	0.1	0
48	ecancermedicalscience. Ecancermedicalscience, 2013, 7, 308.	1.1	56
49	Nuclear EGFRvIIIâ€STAT5b complex contributes to glioblastoma cell survival by direct activation of the Bclâ€XL promoter. International Journal of Cancer, 2013, 132, 509-520.	5.1	41
50	Forkhead Box M1 Is Regulated by Heat Shock Factor 1 and Promotes Glioma Cells Survival under Heat Shock Stress. Journal of Biological Chemistry, 2013, 288, 1634-1642.	3.4	46
51	Deformable Anatomic Templates Improve Analysis of Gliomas With Minimal Mass Effect in Eloquent Areas. Neurosurgery, 2013, 73, 534-542.	1.1	10
52	Subcortical Injury Is an Independent Predictor of Worsening Neurological Deficits Following Awake Craniotomy Procedures. Neurosurgery, 2013, 72, 160-169.	1.1	70
53	The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma. Journal of Clinical Investigation, 2013, 123, 855-65.	8.2	159
54	Letter to the editor: Glioblastoma resection. Journal of Neurosurgery, 2012, 116, 1166-1168.	1.6	3

#	Article	IF	CITATIONS
55	Metastatic brain tumors. , 2012, , 864-892.		16
56	Analysis of Phosphotyrosine Signaling in Glioblastoma Identifies STAT5 as a Novel Downstream Target of ΔEGFR. Journal of Proteome Research, 2011, 10, 1343-1352.	3.7	44
57	Multiple craniotomies in the management of multifocal and multicentric glioblastoma. Journal of Neurosurgery, 2011, 114, 576-584.	1.6	77
58	Outcomes and Prognostic Factors for Patients With Brainstem Metastases Undergoing Stereotactic Radiosurgery. Neurosurgery, 2011, 69, 796-806.	1.1	60
59	FoxM1 Promotes Î ² -Catenin Nuclear Localization and Controls Wnt Target-Gene Expression and Glioma Tumorigenesis. Cancer Cell, 2011, 20, 427-442.	16.8	505
60	Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro-Oncology, 2011, 13, 324-333.	1.2	306
61	Glioma-Associated Cytomegalovirus Mediates Subversion of the Monocyte Lineage to a Tumor Propagating Phenotype. Clinical Cancer Research, 2011, 17, 4642-4649.	7.0	116
62	Factors influencing the risk of local recurrence after resection of a single brain metastasis. Journal of Neurosurgery, 2010, 113, 181-189.	1.6	146
63	Adjuvant whole-brain radiation therapy after surgical resection of single brain metastases. Neuro-Oncology, 2010, 12, 711-719.	1.2	54
64	Intratumoral Mediated Immunosuppression is Prognostic in Genetically Engineered Murine Models of Glioma and Correlates to Immunotherapeutic Responses. Clinical Cancer Research, 2010, 16, 5722-5733.	7.0	71
65	FoxM1B Regulates NEDD4-1 Expression, Leading to Cellular Transformation and Full Malignant Phenotype in Immortalized Human Astrocytes. Cancer Research, 2010, 70, 2951-2961.	0.9	76
66	Glioma-Associated Cancer-Initiating Cells Induce Immunosuppression. Clinical Cancer Research, 2010, 16, 461-473.	7.0	212
67	Glioblastoma Cancer-Initiating Cells Inhibit T-Cell Proliferation and Effector Responses by the Signal Transducers and Activators of Transcription 3 Pathway. Molecular Cancer Therapeutics, 2010, 9, 67-78.	4.1	253
68	Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma. Journal of Clinical Oncology, 2010, 28, 4722-4729.	1.6	702
69	Utilization of Intraoperative Motor Mapping in Glioma Surgery with High-Field Intraoperative Magnetic Resonance Imaging. Stereotactic and Functional Neurosurgery, 2010, 88, 345-352.	1.5	24
70	Surgical management of lateral-ventricle metastases: report of 29 cases in a single-institution experience. Journal of Neurosurgery, 2010, 112, 1046-1055.	1.6	27
71	Immediate morbidity and mortality associated with transcallosal resection of tumors of the third ventricle. Journal of Clinical Neuroscience, 2010, 17, 830-836.	1.5	20
72	Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro-Oncology, 2010, 12, 1113-1125.	1.2	530

#	Article	IF	CITATIONS
73	Brain Metastasis. , 2010, , 345-361.		1
74	IGFBP2 is a candidate biomarker for <i>Ink4a-Arf</i> status and a therapeutic target for high-grade gliomas. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 16675-16679.	7.1	52
75	Asymptomatic cerebellopontine angle and lateral ventricle metastases from renal cell carcinoma: case report and literature review. Journal of Neuro-Oncology, 2009, 91, 101-106.	2.9	7
76	Management of brain metastases: the indispensable role of surgery. Journal of Neuro-Oncology, 2009, 92, 275-282.	2.9	133
77	Simultaneous phosphorylation of p53 at serine 15 and 20 induces apoptosis in human glioma cells by increasing expression of pro-apoptotic genes. Journal of Neuro-Oncology, 2009, 92, 357-371.	2.9	29
78	yuDetecting the percent of peripheral blood mononuclear cells displaying p-STAT-3 in malignant glioma patients. Journal of Translational Medicine, 2009, 7, 92.	4.4	7
79	COMPARATIVE RISK OF LEPTOMENINGEAL DISSEMINATION OF CANCER AFTER SURGERY OR STEREOTACTIC RADIOSURGERY FOR A SINGLE SUPRATENTORIAL SOLID TUMOR METASTASIS. Neurosurgery, 2009, 64, 664-676.	1.1	124
80	AWAKE CRANIOTOMY FOR BRAIN TUMORS NEAR ELOQUENT CORTEX. Neurosurgery, 2009, 64, 836-846.	1.1	210
81	IMPACT OF INTRAOPERATIVE HIGH-FIELD MAGNETIC RESONANCE IMAGING GUIDANCE ON GLIOMA SURGERY. Neurosurgery, 2009, 64, 1073-1081.	1.1	178
82	Comparative risk of leptomeningeal disease after resection or stereotactic radiosurgery for solid tumor metastasis to the posterior fossa. Journal of Neurosurgery, 2008, 108, 248-257.	1.6	154
83	Monitoring autophagy in glioblastoma with antibody against isoform B of human microtubule-associated protein 1 light chain 3. Autophagy, 2008, 4, 467-475.	9.1	126
84	The Incidence, Correlation with Tumor-Infiltrating Inflammation, and Prognosis of Phosphorylated STAT3 Expression in Human Gliomas. Clinical Cancer Research, 2008, 14, 8228-8235.	7.0	174
85	Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: Case study. Neuro-Oncology, 2008, 10, 98-103.	1.2	109
86	Phosphorylation of Thr18 and Ser20 of p53 in Ad-p53–induced apoptosis. Neuro-Oncology, 2008, 10, 275-291.	1.2	29
87	FoxM1B Transcriptionally Regulates Vascular Endothelial Growth Factor Expression and Promotes the Angiogenesis and Growth of Glioma Cells. Cancer Research, 2008, 68, 8733-8742.	0.9	184
88	Molecular Basis for the Critical Role of Suppressor of Cytokine Signaling-1 in Melanoma Brain Metastasis. Cancer Research, 2008, 68, 9634-9642.	0.9	75
89	Metastatic Brain Tumors: Surgery Perspective. , 2008, , 193-199.		2
90	Telomere 3′ overhangâ€specific DNA oligonucleotides induce autophagy in malignant glioma cells. FASEB Journal, 2007, 21, 2918-2930.	0.5	57

#	Article	IF	CITATIONS
91	Phosphorylated Pak1 Level in the Cytoplasm Correlates with Shorter Survival Time in Patients with Glioblastoma. Clinical Cancer Research, 2007, 13, 6603-6609.	7.0	59
92	Complications of Stereotactic Radiosurgery in Patients With Brain Metastases. Neurosurgery Quarterly, 2007, 17, 81-91.	0.1	2
93	Evidence That Curcumin Suppresses the Growth of Malignant Gliomas in Vitro and in Vivo through Induction of Autophagy: Role of Akt and Extracellular Signal-Regulated Kinase Signaling Pathways. Molecular Pharmacology, 2007, 72, 29-39.	2.3	480
94	Radiosurgery in the treatment of brain metastases: critical review regarding complications. Neurosurgical Review, 2007, 31, 1-9.	2.4	26
95	FoxM1B Is Overexpressed in Human Glioblastomas and Critically Regulates the Tumorigenicity of Glioma Cells. Cancer Research, 2006, 66, 3593-3602.	0.9	292
96	Comments about the prospective randomized trial by Aoyama et al. World Neurosurgery, 2006, 66, 459-460.	1.3	10
97	Resident training in neurosurgical oncology: results of the survey of North American training programs by the AANS/CNS Section on Tumors. Journal of Neuro-Oncology, 2006, 77, 241-246.	2.9	13
98	Autophagic Cell Death of Malignant Glioma Cells Induced by a Conditionally Replicating Adenovirus. Journal of the National Cancer Institute, 2006, 98, 625-636.	6.3	157
99	Activation of Stat3 in Human Melanoma Promotes Brain Metastasis. Cancer Research, 2006, 66, 3188-3196.	0.9	366
100	Neurosurgical Oncology at The University of Texas M. D. Anderson Cancer Center: Its Genesis and Evolution. Neurosurgery, 2005, 56, 841-850.	1.1	3
101	Resection of brain metastases previously treated with stereotactic radiosurgery. Journal of Neurosurgery, 2005, 102, 209-215.	1.6	65
102	The role of autophagy in cancer development and response to therapy. Nature Reviews Cancer, 2005, 5, 726-734.	28.4	1,581
103	Δ24-hyCD adenovirus suppresses glioma growth in vivo by combining oncolysis and chemosensitization. Cancer Gene Therapy, 2005, 12, 284-294.	4.6	62
104	Many human medulloblastoma tumors overexpress repressor element-1 silencing transcription (REST)/neuron-restrictive silencer factor, which can be functionally countered by REST-VP16. Molecular Cancer Therapeutics, 2005, 4, 343-349.	4.1	94
105	Mechanisms of action of rapamycin in gliomas. Neuro-Oncology, 2005, 7, 1-11.	1.2	27
106	Expression of Activated Signal Transducer and Activator of Transcription 3 Predicts Expression of Vascular Endothelial Growth Factor in and Angiogenic Phenotype of Human Gastric Cancer. Clinical Cancer Research, 2005, 11, 1386-1393.	7.0	134
107	Prognostic Effect of Epidermal Growth Factor Receptor and EGFRvIII in Glioblastoma Multiforme Patients. Clinical Cancer Research, 2005, 11, 1462-1466.	7.0	446
108	Inhibition of the DNA-Dependent Protein Kinase Catalytic Subunit Radiosensitizes Malignant Glioma Cells by Inducing Autophagy. Cancer Research, 2005, 65, 4368-4375.	0.9	162

#	Article	IF	CITATIONS
109	Outcome variation among "radioresistant" brain metastases treated with stereotactic radiosurgery. Neurosurgery, 2005, 56, 936-45; discussion 936-45.	1.1	97
110	Cystic glioblastoma multiforme: survival outcomes in 22 cases. Journal of Neurosurgery, 2004, 100, 61-67.	1.6	56
111	Identification of Necrosis-Associated Genes in Glioblastoma by cDNA Microarray Analysis. Clinical Cancer Research, 2004, 10, 212-221.	7.0	66
112	Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene, 2004, 23, 3550-3560.	5.9	487
113	Brain Metastases in Patients with Ovarian Carcinoma: Prognostic Factors and Outcome. Journal of Neuro-Oncology, 2004, 66, 313-325.	2.9	114
114	Chairman's Reflection on the Past, Present and Future of Neurosurgical Oncology. Journal of Neuro-Oncology, 2004, 69, 19-23.	2.9	3
115	Carcinoid metastasis to the brain. Cancer, 2004, 101, 2605-2613.	4.1	75
116	Stereotactic radiosurgical treatment in 103 patients for 153 cerebral melanoma metastases. International Journal of Radiation Oncology Biology Physics, 2004, 59, 1097-1106.	0.8	168
117	Part II: Surgery versus radiosurgery for brain metastasis: surgical advantages and radiosurgical myths. Clinical Neurosurgery, 2004, 51, 255-63.	0.2	5
118	Metastasis of esophageal carcinoma to the brain. Cancer, 2003, 98, 1925-1933.	4.1	114
119	Neoplasm Surgical Neurology - Volume 60, Issue 3. World Neurosurgery, 2003, 60, 225-226.	1.3	9
120	Preclinical Characterization of the Antiglioma Activity of a Tropism-Enhanced Adenovirus Targeted to the Retinoblastoma Pathway. Journal of the National Cancer Institute, 2003, 95, 652-660.	6.3	314
121	Neuropsychological Effects of Third Ventricle Tumor Surgery. Neurosurgery, 2003, 52, 791-798.	1.1	39
122	The Role of Tumor Size in the Radiosurgical Management of Patients with Ambiguous Brain Metastases. Neurosurgery, 2003, 53, 272-281.	1.1	101
123	Optimizing Outcomes with Maximal Surgical Resection of Malignant Gliomas. Cancer Control, 2003, 10, 109-114.	1.8	72
124	Toward better early-phase brain tumor clinical trials: A reappraisal of current methods and proposals for future strategies. Neuro-Oncology, 2002, 4, 268-277.	1.2	41
125	Radical Resection of Glioblastoma. Contemporary Neurosurgery, 2002, 24, 1-5.	0.1	4
126	Management of Brain Metastases. Neurosurgery Quarterly, 2002, 12, 79-85.	0.1	3

#	Article	IF	CITATIONS
127	Necrosis and Glioblastoma: A Friend or a Foe? A Review and a Hypothesis. Neurosurgery, 2002, 51, 2-13.	1.1	195
128	A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. Journal of Neurosurgery, 2001, 95, 190-198.	1.6	2,484
129	Surgical resection of intrinsic insular tumors: complication avoidance. Journal of Neurosurgery, 2001, 95, 638-650.	1.6	193
130	Surgical Resection of Calvarial Metastases Overlying Dural Sinuses. Neurosurgery, 2001, 48, 745-755.	1.1	4
131	Surgical Resection of Calvarial Metastases Overlying Dural Sinuses. Neurosurgery, 2001, 48, 745-755.	1.1	30
132	Surgical management of brain metastases. Current Oncology Reports, 2001, 3, 476-483.	4.0	41
133	Limitations of stereotactic biopsy in the initial management of gliomas. Neuro-Oncology, 2001, 3, 193-200.	1.2	329
134	Practice parameters for the management of single brain metastasis. Neurosurgical Focus, 2000, 9, 1-9.	2.3	15
135	Stereotactic radiosurgery for brain metastases:Results and prognostic factors. International Journal of Cancer, 2000, 90, 157-162.	5.1	45
136	Effects of radiation on the levels of MMP-2, MMP-9 and TIMP-1 during morphogenic glial-endothelial cell interactions. International Journal of Cancer, 2000, 88, 766-771.	5.1	40
137	Antiangiogenesis therapeutic strategies and clinical implications for brain tumors. , 2000, 50, 189-200.		73
138	Brain Metastasis: Steel Knife or Gamma Knife?. Annals of Surgical Oncology, 2000, 7, 323-324.	1.5	6
139	Surgical Management of Intracerebral Metastases. Seminars in Neurosurgery, 2000, 11, 0351-0364.	0.0	Ο
140	An implantable guide-screw system for brain tumor studies in small animals. Journal of Neurosurgery, 2000, 92, 326-333.	1.6	208
141	Basic surgical techniques in the resection of malignant gliomas. Journal of Neuro-Oncology, 1999, 42, 215-226.	2.9	35
142	Extent of resection in malignant gliomas: a critical summary. Journal of Neuro-Oncology, 1999, 42, 303-305.	2.9	82
143	Downregulation of the urokinase-type plasminogen activator receptor through inhibition of translation by antisense oligonucleotide suppresses invasion of human glioblastoma cells. Clinical and Experimental Metastasis, 1999, 17, 617-621.	3.3	18
144	Altered actin cytoskeleton and inhibition of matrix metalloproteinase expression by vanadate and phenylarsine oxide, inhibitors of phosphotyrosine phosphatases: Modulation of migration and invasion of human malignant glioma cells. Molecular Carcinogenesis, 1999, 26, 274-285.	2.7	28

#	Article	IF	CITATIONS
145	Volumetric measurement of brain tumors from MR imaging. Journal of Neuro-Oncology, 1998, 37, 87-93.	2.9	50
146	Expression and localization of urokinase-type plasminogen activator in human spinal column tumors. Clinical and Experimental Metastasis, 1998, 16, 713-719.	3.3	4
147	Expression and role of matrix metalloproteinases MMP-2 and MMP-9 in human spinal column tumors. Clinical and Experimental Metastasis, 1998, 16, 721-728.	3.3	33
148	Surgical treatment of metastatic brain tumors. , 1998, 14, 53-63.		39
149	Elevated Levels of Mr92,000 Type IV Collagenase during Tumor Growthin Vivo. Biochemical and Biophysical Research Communications, 1998, 251, 632-636.	2.1	48
150	Induction of Matrix Metalloproteinase-9 Requires a Polymerized Actin Cytoskeleton in Human Malignant Glioma Cells. Journal of Biological Chemistry, 1998, 273, 13545-13551.	3.4	69
151	Metastatic brain tumors with dural extension. Journal of Neurosurgery, 1998, 89, 552-558.	1.6	29
152	Neurosurgical Outcomes in a Modern Series of 400 Craniotomies for Treatment of Parenchymal Tumors. Neurosurgery, 1998, 42, 1044-1055.	1.1	603
153	Management of Cerebral Metastases: The Role of Surgery. Cancer Control, 1998, 5, 124-129.	1.8	10
154	Visual Failure Caused by Suprasellar Extramedullary Hematopoiesis in Beta Thalassemia: Case Report. Neurosurgery, 1998, 42, 926-926.	1.1	0
155	In vitro inhibition of human glioblastoma cell line invasiveness by antisense uPA receptor. Oncogene, 1997, 14, 1351-1359.	5.9	98
156	Adenovirus-mediated p16/CDKN2 gene transfer suppresses glioma invasion in vitro. Oncogene, 1997, 15, 2049-2057.	5.9	94
157	Inhibition of in vivo tumorigenicity and invasiveness of a human glioblastoma cell line transfected with antisense uPAR vectors. Clinical and Experimental Metastasis, 1997, 15, 440-446.	3.3	70
158	Effect of cisplatin and BCNU on MMP-2 levels in human glioblastoma cell lines in vitro. Clinical and Experimental Metastasis, 1997, 15, 361-367.	3.3	17
159	Regulation of MMP-9 (92 kDa type IV collagenase/gelatinase B) expression in stromal cells of human giant cell tumor of bone. Clinical and Experimental Metastasis, 1997, 15, 400-409.	3.3	16
160	Cisplatin but not BCNU inhibits urokinase-type plasminogen activator levels in human glioblastoma cell lines in vitro. Clinical and Experimental Metastasis, 1997, 15, 447-452.	3.3	1
161	Lesions of the calvaria: Surgical experience with 42 patients. Annals of Surgical Oncology, 1997, 4, 28-36.	1.5	28
162	External radiation of brain metastases from renal carcinoma: A retrospective study of 119 patients from the M. D. Anderson Cancer Center. International Journal of Radiation Oncology Biology Physics, 1997, 37, 753-759.	0.8	183

#	Article	IF	CITATIONS
163	Altered in vitro spreading and cytoskeletal organization in human glioma cells by downregulation of urokinase receptor. Molecular Carcinogenesis, 1997, 20, 355-365.	2.7	26
164	Modulation of matrix metalloprotease-2 and invasion in human glioma cells by α3β1 integrin. Cancer Letters, 1996, 103, 201-208.	7.2	75
165	Expression and the role of cathepsin H in human glioma progression and invasion. Cancer Letters, 1996, 104, 121-126.	7.2	53
166	Expression of cathepsin D during the progression of human gliomas. Neuroscience Letters, 1996, 208, 171-174.	2.1	48
167	Invasive pattern of lac-Z-transfected human glioblastoma cells in nude mice brain. Cancer Letters, 1996, 110, 225-231.	7.2	8
168	Surgery versus radiosurgery in the treatment of brain metastasis. Journal of Neurosurgery, 1996, 84, 748-754.	1.6	287
169	Surgical Management of Cerebral Metastases. Neurosurgery Clinics of North America, 1996, 7, 459-484.	1.7	58
170	Expression of cysteine protease inhibitors in human gliomas and meningiomas. Clinical and Experimental Metastasis, 1996, 14, 344-350.	3.3	30
171	Prognostic significance of preoperative MRI scans in glioblastoma multiforme. Journal of Neuro-Oncology, 1996, 27, 65-73.	2.9	227
172	Expression and immunohistochemical localization of cathepsin L during the progression of human gliomas. Clinical and Experimental Metastasis, 1996, 14, 27-34.	3.3	66
173	Surgical treatment of metastatic brain tumors. Journal of Neuro-Oncology, 1996, 27, 269-277.	2.9	63
174	Use of intraoperative ultrasound for localizing tumors and determining the extent of resection: a comparative study with magnetic resonance imaging. Journal of Neurosurgery, 1996, 84, 737-741.	1.6	208
175	Modulation of Serine Proteinases and Metalloproteinases During Morphogenic Glialâ€Endothelial Interactions. Journal of Neurochemistry, 1996, 66, 1657-1664.	3.9	11
176	Plasminogen Activator Inhibitor-1 in Brain Tumors. Neurosurgery, 1995, 36, 375-381.	1.1	31
177	Expression of 72 kDa and 92 kDa type IV collagenases from human giant-cell tumor of bone. Clinical and Experimental Metastasis, 1995, 13, 420-426.	3.3	25
178	Overexpression and localization of cathepsin B during the progression of human gliomas. Clinical and Experimental Metastasis, 1995, 13, 49-56.	3.3	108
179	Expression of tissue inhibitors of metalloproteinases: negative regulators of human glioblastoma invasion in vivo. Clinical and Experimental Metastasis, 1995, 13, 57-62.	3.3	91
180	Advances in Surgery for Brain Tumors. Neurologic Clinics, 1995, 13, 757-771.	1.8	19

#	Article	IF	CITATIONS
181	Aggressive meningeal tumors: review of a series. Journal of Neurosurgery, 1995, 82, 17-27.	1.6	104
182	Reoperation for recurrent metastatic brain tumors. Journal of Neurosurgery, 1995, 83, 600-604.	1.6	158
183	Plasminogen Activator Inhibitor-1 in Brain Tumors. Neurosurgery, 1995, 36, 375???381.	1.1	3
184	Role of plasminogen activator and of 92-KDa type IV collagenase in glioblastoma invasion using anin vitro Matrigel model. Journal of Neuro-Oncology, 1994, 18, 129-138.	2.9	67
185	Prognostic significance of proteolytic enzymes in human brain tumors. Journal of Neuro-Oncology, 1994, 22, 101-110.	2.9	75
186	Activities, localizations, and roles of serine proteases and their inhibitors in human brain tumor progression. Journal of Neuro-Oncology, 1994, 22, 139-151.	2.9	34
187	Modulation of fibrinolysis by ionizing radiation. Journal of Neuro-Oncology, 1994, 22, 161-171.	2.9	12
188	Induction of tissue-type plasminogen activator and 72-kDa type-IV collagenase by ionizing radiation in rat astrocytes. International Journal of Cancer, 1994, 56, 214-218.	5.1	40
189	Management of metastatic brain tumors. Annals of Surgical Oncology, 1994, 1, 169-178.	1.5	45
190	Elevated Levels of Plasminogen Activators in the Pathogenesis of Delayed Radiation Damage in Rat Cervical Spinal Cord In Vivo. Radiation Research, 1994, 138, 386.	1.5	8
191	Plasminogen activator inhibitor-1 in the pathogenesis of delayed radiation damage in rat spinal cord in vivo. Journal of Neurosurgery, 1994, 81, 381-387.	1.6	14
192	Increased levels of plasminogen activator inhibitor-1 (PAI-1) in human brain tumors. Journal of Neuro-Oncology, 1993, 17, 215-221.	2.9	32
193	Surgical treatment of multiple brain metastases. Journal of Neurosurgery, 1993, 79, 210-216.	1.6	487
194	Intracranial Osteolytic Malignant Meningiomas Appearing as Extracranial Soft-Tissue Masses. Neurosurgery, 1992, 30, 932-934.	1.1	30
195	Postoperative venous thromboembolism and brain tumors: part III. Biochemical profile. Journal of Neuro-Oncology, 1992, 14, 113-8.	2.9	10
196	Postoperative venous thromboembolism and brain tumors: part I. Clinical profile. Journal of Neuro-Oncology, 1992, 14, 119-25.	2.9	52
197	Postoperative venous thromboembolism and brain tumors: part II. Hemostatic profile. Journal of Neuro-Oncology, 1992, 14, 127-34.	2.9	20
198	Intracranial Osteolytic Malignant Meningiomas Appearing as Extracranial Soft-Tissue Masses. Neurosurgery, 1992, 30, 932-934.	1.1	45

#	Article	IF	CITATIONS
199	Neurosurgery issues in oncology. Current Opinion in Oncology, 1991, 3, 459-466.	2.4	7
200	Biological significance of tissue plasminogen activator content in brain tumors. Journal of Neurosurgery, 1991, 74, 480-486.	1.6	52
201	Presence and Significance of $\hat{I}\pm 1$ -Antitrypsin in Human Brain Tumors. , 1990, , 293-299.		1
202	Plasminogen activator activity and molecular weight patterns in human brain tumors. Journal of Neurosurgery, 1988, 68, 73-79.	1.6	42
203	Alpha-1-antitrypsin in human brain tumors. Journal of Neurosurgery, 1987, 67, 258-262.	1.6	26
204	Brain tumors and thromboembolic complications. World Neurosurgery, 1987, 28, 163.	1.3	19
205	Immunohistochemical demonstration of alpha-1-proteinase inhibitor in brain tumors. Cancer, 1987, 60, 804-809.	4.1	17
206	Intraoperative Chemical Hemostasis in Neurosurgery. Neurosurgery, 1986, 18, 223-233.	1.1	70
207	Successful Laser-assisted Excision of a Metastatic Midbrain Tumor. Neurosurgery, 1986, 18, 795-797.	1.1	25
208	The morphology and biologic behavior of human glioblastoma growing in nude mice. Cancer, 1986, 58, 1061-1069.	4.1	14
209	Antifibrinolytic therapy of experimentally grown malignant brain tumors. Journal of Neurosurgery, 1986, 64, 263-268.	1.6	18
210	Superior Sagittal Sinus Thrombosis after Closed Head Injury. Neurosurgery, 1985, 16, 825-828.	1.1	30
211	Brain Tumor and Achondroplasia: A Case Report and Review of the Literature. Neurosurgery, 1984, 15, 111-113.	1.1	4
212	Brain Tumors and Plasmin Inhibitors. Neurosurgery, 1984, 15, 795-800.	1.1	31
213	Brain Tumors and Plasmin Inhibitors. Neurosurgery, 1984, 15, 795-800.	1.1	17
214	Massive Preoperative Pulmonary Embolism and Suprasellar Brain Tumor: Case Report and Review of the Literature. Neurosurgery, 1984, 15, 566-571.	1.1	21
215	Chronic Disseminated Intravascular Coagulation and Metastatic Brain Tumor: A Case Report and Review of the Literature. Neurosurgery, 1983, 12, 580-584.	1.1	27
216	Spinal epidural extramedullary hematopoiesis with cord compression in a patient with refractory sideroblastic anemia. Journal of Neurosurgery, 1982, 57, 399-406.	1.6	36

#	Article	IF	CITATIONS
217	Brain Metastasis from Cancer of an Unknown Primary Site. , 0, , 292-308.		0
218	Akt inhibitor shows anticancer and radiosensitizing effects in malignant glioma cells by inducing autophagy. International Journal of Oncology, 0, , .	3.3	54